A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence
暂无分享,去创建一个
Christine Fletcher | Anthea Sutton | Gerald Downey | John W Stevens | A. Sutton | J. Stevens | C. Fletcher | Gerald Downey
[1] Eric Q. Wu,et al. Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes Mellitus , 2011, Clinical drug investigation.
[2] Irina Proskorovsky,et al. Simulation and Matching-Based Approaches for Indirect Comparison of Treatments , 2015, PharmacoEconomics.
[3] Elizabeth A Stuart,et al. Matching methods for causal inference: A review and a look forward. , 2010, Statistical science : a review journal of the Institute of Mathematical Statistics.
[4] P. Lorigan,et al. Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma. , 2012, The oncologist.
[5] Anthony O'Hagan,et al. Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.
[6] Nicky J Welton,et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE , 2016 .
[7] Zhimei Liu,et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples , 2011, Expert opinion on pharmacotherapy.
[8] J. P. Perez Ruixo,et al. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. , 2014, The Journal of clinical endocrinology and metabolism.
[9] Alan Brnabic,et al. Inclusion Of Multiple Studies In Matching Adjusted Indirect Comparisons (Maic) , 2015 .
[10] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[12] Catherine P. Bradshaw,et al. The use of propensity scores to assess the generalizability of results from randomized trials , 2011, Journal of the Royal Statistical Society. Series A,.
[13] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, BMJ : British Medical Journal.
[14] Nicky J Welton,et al. NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making , 2011 .
[15] A. E. Ades,et al. Absolute or relative effects? Arm‐based synthesis of trial data , 2015, Research synthesis methods.
[16] David H. Salinger,et al. A dose–response Meta‐Analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis , 2011, Clinical pharmacology and therapeutics.
[17] S. Duffull,et al. A model‐based meta‐analysis of the influence of factors that impact adherence to medications , 2015, Journal of clinical pharmacy and therapeutics.
[18] Gary C. Brown,et al. Comparative effectiveness , 2009, Current opinion in ophthalmology.
[19] David C Hoaglin,et al. An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis? , 2012, Expert opinion on pharmacotherapy.
[20] S. Palmer,et al. Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma , 2016, Advances in Therapy.
[21] Jae Eun Ahn,et al. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Jens Hainmueller,et al. Entropy Balancing for Causal Effects: A Multivariate Reweighting Method to Produce Balanced Samples in Observational Studies , 2012, Political Analysis.
[23] S M Goring,et al. Disconnected by design: analytic approach in treatment networks having no common comparator , 2016, Research synthesis methods.
[24] D Mawdsley,et al. Model‐Based Network Meta‐Analysis: A Framework for Evidence Synthesis of Clinical Trial Data , 2016, CPT: pharmacometrics & systems pharmacology.
[25] Liang Jin,et al. Utilization of model-based meta-analysis to delineate the net efficacy of taspoglutide from the response of placebo in clinical trials , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.
[26] Stephen Senn,et al. Controversies concerning randomization and additivity in clinical trials , 2004, Statistics in medicine.
[27] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 1 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] Andrea Manca,et al. NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .
[29] Mei Lu,et al. Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology , 2013, CNS Drugs.
[30] Nicola J Cooper,et al. Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes , 2014, BMC Medical Research Methodology.
[31] J. Gibbs,et al. Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results , 2012, Journal of clinical pharmacology.
[32] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 7 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[33] Mei Lu,et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] Douglas G Altman,et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses , 2003, BMJ : British Medical Journal.
[35] Mats O Karlsson,et al. A linearization approach for the model‐based analysis of combined aggregate and individual patient data , 2014, Statistics in medicine.
[36] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] David J Spiegelhalter,et al. A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.
[38] J. Weber,et al. Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma , 2013, Clinical Cancer Research.
[39] M. Kalaycio,et al. Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons , 2012, Leukemia & lymphoma.
[40] Eric Q. Wu,et al. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials , 2011, Current medical research and opinion.
[41] B. Monz,et al. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus , 2013, BMJ Open.
[42] B. Hamrén,et al. Longitudinal Model‐Based Meta‐Analysis in Rheumatoid Arthritis: An Application Toward Model‐Based Drug Development , 2012, Clinical pharmacology and therapeutics.
[43] Donald E Mager,et al. Population‐based meta‐analysis of furosemide pharmacokinetics , 2014, Biopharmaceutics & drug disposition.
[44] D R Mould,et al. Model‐Based Meta‐Analysis: An Important Tool for Making Quantitative Decisions During Drug Development , 2012, Clinical pharmacology and therapeutics.
[45] Gavin Giovannoni,et al. No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis , 2014, Advances in Therapy.
[46] Eric Q. Wu,et al. Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.
[47] Léo R. Belzile,et al. A Bayesian view of doubly robust causal inference , 2016, 1701.04093.
[48] Fang Chen,et al. Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.
[49] Lei Nie,et al. Likelihood reweighting methods to reduce potential bias in noninferiority trials which rely on historical data to make inference , 2013, 1311.7485.
[50] F. Wiegand,et al. Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[51] Roland R. Ramsahai,et al. Evaluating treatment effectiveness in patient subgroups: a comparison of propensity score methods with an automated matching approach , 2012, The international journal of biostatistics.
[52] D. Mould. Models for Disease Progression: New Approaches and Uses , 2012, Clinical pharmacology and therapeutics.
[53] S. Shoaf,et al. Population‐based meta‐analysis of hydrochlorothiazide pharmacokinetics , 2013, Biopharmaceutics & drug disposition.
[54] Alex J. Sutton,et al. Evidence Synthesis for Decision Making 2 , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.
[55] H. Kaufman,et al. Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.
[56] Richard M Nixon,et al. Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension , 2015, BMC Medical Research Methodology.
[57] Roland R. Ramsahai,et al. From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects , 2015 .
[58] F. Mercier,et al. A Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain , 2014, Pain and Therapy.
[59] D. DeAngelo,et al. One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison , 2015, Current medical research and opinion.
[60] Alan Brnabic,et al. Reweighting Rct Evidence To Better Reflect Real Life: A Case Study of The Innovation Medicines Initiative , 2016 .
[61] Z. Kadziola,et al. Alternative Weighting Approaches For Matching Adjusted Indirect Comparisons (Maic) , 2015 .
[62] E. Stuart,et al. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes , 2015, Statistical methods in medical research.
[63] K. Jack Ishak,et al. No Head-to-Head Trial? Simulate the Missing Arms , 2012, PharmacoEconomics.
[64] Liang Zhao,et al. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development. , 2012, Journal of pharmaceutical sciences.
[65] Jeremy E. Oakley,et al. Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .
[66] M. Gibbs,et al. Model‐Based Meta‐Analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond , 2011, Clinical pharmacology and therapeutics.
[67] M. Danhof,et al. Pharmacokinetic–pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia Part I: The use of PANSS total score and clinical utility , 2013, Schizophrenia Research.
[68] Mei Lu,et al. Comparative effectiveness research using matching‐adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention‐deficit/hyperactivity disorder and comorbid oppositional defiant disorder , 2012, Pharmacoepidemiology and drug safety.